Published in Biochem Pharmacol on November 01, 1980
Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci U S A (1991) 2.30
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology (1999) 2.11
Possible involvement of nitric oxide in long-term potentiation. Eur J Pharmacol (1991) 1.72
Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci U S A (1993) 1.25
A sustained effect of electroconvulsive shock on the turnover of norepinephrine in the central nervous system of the rat. Proc Natl Acad Sci U S A (1967) 1.23
Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J Med Chem (1999) 1.18
Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci (1989) 1.03
Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci Lett (1992) 1.02
Increase in rat brain tyrosine hydroxylase activity produced by electroconvulsive shock. Proc Natl Acad Sci U S A (1969) 1.00
A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically. Br J Pharmacol (1993) 0.98
Evidence for a role of tachykinins as sensory transmitters in the activation of micturition reflex. Neuroscience (1993) 0.94
RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J Pharmacol Exp Ther (2001) 0.94
Comparison in different tissue preparations of the in vitro pharmacological profile of RP 67580, a new non-peptide substance P antagonist. Neuropeptides (1992) 0.92
Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol (1995) 0.92
Hypotensive activity of PAF-acether in rats. Agents Actions (1982) 0.91
[Pro9]SP and [pGlu6, Pro9]SP(6-11) interact with two different receptors in the guinea-pig ileum as demonstrated with new SP antagonists. Neuropeptides (1992) 0.90
CholecystokininA and cholecystokininB receptors in neurons of the brainstem solitary complex of the rat: pharmacological identification. J Pharmacol Exp Ther (1992) 0.89
Studies on the immunosuppressive activity of L-asparaginase. Recent Results Cancer Res (1970) 0.89
The neuroleptics. 4. Toxicity and side effects in man and in the laboratory animal. Mod Probl Pharmacopsychiatry (1970) 0.89
Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells. Neurosci Lett (1992) 0.89
Selective agonists of NK-2 binding sites highly active on rat portal vein (NK-3 bioassay). Neuropeptides (1991) 0.88
CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats. Psychopharmacology (Berl) (1994) 0.88
[Toxicologic study and experimental antitumor activity of rubidomycin (13,057 R.P.)]. Pathol Biol (1967) 0.88
Glutamate uptake is decreased tardively in the spinal cord of FALS mice. Neuroreport (1998) 0.88
Variations in affinities for the NK1 receptor: differences between the non-peptide substance P antagonists RP 67580 and CP-96,345 and the agonist septide. Regul Pept (1993) 0.88
Inhibition of neurogenic inflammation in the meninges by a non-peptide NK1 receptor antagonist, RP 67580. Eur J Pharmacol (1993) 0.87
Septide: an agonist for the NK1 receptor acting at a site distinct from substance P. Mol Pharmacol (1994) 0.87
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden. Bioorg Med Chem Lett (2000) 0.87
Pharmacological studies on zopiclone. Pharmacology (1983) 0.87
Brain receptors and zopiclone. Pharmacology (1983) 0.87
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience (1996) 0.86
[RP 67580, a potent and selective substance P non-peptide antagonist]. C R Acad Sci III (1992) 0.86
Species differences between [3H] substance P binding in rat and guinea-pig shown by the use of peptide agonists and antagonists. Eur J Pharmacol (1991) 0.86
Differences between cyclopyrrolones (suriclone and zopiclone) and benzodiazepine binding to rat hippocampus photolabelled membranes. Biochem Pharmacol (1983) 0.85
Suriclone: a new cyclopyrrolone derivative recognizing receptors labeled by benzodiazepines in rat hippocampus and cerebellum. J Neurochem (1983) 0.85
Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dendrotoxin I in the rat. Eur J Pharmacol (1991) 0.85
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur J Neurosci (2000) 0.85
Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.84
Excitatory effects of cholecystokinin in rat hippocampus: pharmacological response compatible with 'central'- or B-type CCK receptors. Brain Res (1988) 0.84
Effects of halothane and nitrous oxide anaesthesia on 5-HT turn-over in the rat brain. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.83
Distribution of neurokinin B in rat spinal cord and peripheral tissues: comparison with neurokinin A and substance P and effects of neonatal capsaicin treatment. Neuroscience (1992) 0.83
Riluzole, a glutamate antagonist, enhances slow wave and REM sleep in rats. Neurosci Lett (1988) 0.83
Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG. J Neurochem (1993) 0.83
The determination of picogram levels of 5-HT in biological fluids. J Neurochem (1976) 0.82
Some pharmacological and toxicological studies on ketoprofen. Rheumatol Rehabil (1976) 0.82
The non-peptide neurokinin-1 antagonist, RPR 100893, decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation. Neuroscience (1995) 0.82
Partial chemical characterization of cyclopyrrolones ([3H] suriclone) and benzodiazepines ([3H]flunitrazepam) binding site: differences. Life Sci (1985) 0.82
Molecular determinants of the species selectivity of neurokinin type 1 receptor antagonists. Mol Pharmacol (1995) 0.82
Suriclone, a new anxiolytic of the cyclopyrrolone family: evidence for possible interference with GABAergic systems. Eur J Pharmacol (1984) 0.81
Polyclonal antibodies against the rat NK1 receptor: characterization and localization in the spinal cord. Neuroreport (1992) 0.81
Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone. Pharmacol Biochem Behav (1985) 0.81
[Bucco-dental flora. Sensitivity to antibiotics and value of the spiramycin-metronidazole combination]. Ann Microbiol (Paris) (1973) 0.81
The human galanin receptor: ligand-binding and functional characteristics in the Bowes melanoma cell line. Eur J Pharmacol (1994) 0.81
'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice. Brain Res (1991) 0.81
Preferential decrease in dopamine utilization in prefrontal cortex by zopiclone, diazepam and zolpidem in unstressed rats. J Pharm Pharmacol (1990) 0.81
Ketoprofen (19.583 R.P.) (2-(3-benzoylphenyl)-propionic acid). Main pharmacological properties--outline of toxicological and pharmacokinetic data. Scand J Rheumatol Suppl (1976) 0.81
Further demonstration that [Pro9]-substance P is a potent and selective ligand of NK-1 tachykinin receptors. J Neurochem (1991) 0.81
In vitro and in vivo inhibition by zopiclone of benzodiazepine binding to rodent brain receptors. Life Sci (1979) 0.80
Substance P and neurokinin A variations throughout the rat estrous cycle; comparison with ovariectomized and male rats: II. Trigeminal nucleus and cervical spinal cord. J Neurosci Res (1996) 0.80
Differential ability of tachykinin NK-1 and NK-2 agonists to produce scratching and grooming behaviours in mice. Brain Res (1994) 0.79
Linkage analysis in 16 families with incontinentia pigmenti. Eur J Hum Genet (1997) 0.79
Pharmacological properties and mechanism of action of the cyclopyrrolones. Encephale (1993) 0.79
Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides (1989) 0.79
Differential electrographic patterns for specific mu- and delta-opioid peptides in rats. Eur J Pharmacol (1986) 0.79
[Activity on Trichomonas vaginalis and other chemotherapeutic properties of 1-(2-hydroxyethyl)-2-carbamoyl-5-nitropyrrole (15,960 RP)]. C R Acad Sci Hebd Seances Acad Sci D (1966) 0.79
Substance P and neurokinin A variations throughout the rat estrous cycle; comparison with ovariectomized and male rats: I. Plasma, hypothalamus, anterior and posterior pituitary. J Neurosci Res (1996) 0.79
Stimulatory effect of a specific substance P antagonist (RPR 100893) of the human NK1 receptor on the estradiol-induced LH and FSH surges in the ovariectomized cynomolgus monkey. J Neurosci Res (1997) 0.79
Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc Natl Acad Sci U S A (1988) 0.79
Differential effects of potassium channel blockers on dopamine release from rat striatal slices. J Pharm Pharmacol (1991) 0.78
Riluzole antagonizes the anxiogenic properties of the beta-carboline FG 7142 in rats. Psychopharmacology (Berl) (1989) 0.78
Dopamine metabolism in the mesolimbic and mesocortical dopaminergic systems after single or repeated administrations of neuroleptics. Brain Res (1976) 0.78
The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists. Ann N Y Acad Sci (1994) 0.78
[Study of the pharmacological properties of 3-dimethylsulfonamido 10-(2-dimethylamino-propyl) phenothiazine (8.599 RP)]. Arch Int Pharmacodyn Ther (1966) 0.78
Spiro-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives are mixed AMPA and NMDA glycine-site antagonists active in vivo. Bioorg Med Chem Lett (1999) 0.78
CCK-A and CCK-B receptors enhance olfactory recognition via distinct neuronal pathways. Learn Mem (1999) 0.78
Proconflict and electrocorticographic effects of drugs modulating GABAergic neurotransmission. Psychopharmacology (Berl) (1987) 0.78
Evidence of electrogenicity of the sarcoplasmic reticulum Ca2+ pump as measured with flow dialysis method. FEBS Lett (1981) 0.78
Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur J Pharmacol (1998) 0.78
RP 62203, a 5-hydroxytryptamine2 antagonist, enhances deep NREM sleep in rats. Sleep (1992) 0.78
CGRP in the trigeminal nucleus, spinal cord and hypothalamus: effect of gonadal steroids. Neuropeptides (1996) 0.78
Brain receptors and zopiclone. Int Pharmacopsychiatry (1982) 0.78